AUD25.55
0.20% today
Australia, Apr 03, 07:10 am CET
ISIN
AU000000TLX2
Symbol
TLX
Sector
Industry

Telix Pharmaceuticals Stock price

AUD25.55
-3.41 11.77% 1M
+5.10 24.94% 6M
+0.94 3.82% YTD
+13.55 112.92% 1Y
+20.85 443.62% 3Y
+24.46 2,244.04% 5Y
+24.78 3,218.18% 10Y
Australia, Closing price Thu, Apr 03 2025
-0.05 0.20%
ISIN
AU000000TLX2
Symbol
TLX
Sector
Industry

Key metrics

Market capitalization AUD8.65b
Enterprise Value AUD8.52b
P/E (TTM) P/E ratio 169.54
EV/FCF (TTM) EV/FCF 597.65
EV/Sales (TTM) EV/Sales 10.87
P/S ratio (TTM) P/S ratio 11.04
P/B ratio (TTM) P/B ratio 15.08
Revenue growth (TTM) Revenue growth 55.85%
Revenue (TTM) Revenue AUD783.21m
EBIT (operating result TTM) EBIT AUD73.91m
Free Cash Flow (TTM) Free Cash Flow AUD14.25m
Cash position AUD118.84m
EPS (TTM) EPS AUD0.15
P/E forward 71.33
P/S forward 6.83
EV/Sales forward 6.73
Show more

Is Telix Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Telix Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Telix Pharmaceuticals forecast:

8x Buy
80%
1x Hold
10%
1x Sell
10%

Analyst Opinions

10 Analysts have issued a Telix Pharmaceuticals forecast:

Buy
80%
Hold
10%
Sell
10%

Financial data from Telix Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
783 783
56% 56%
100%
- Direct Costs 273 273
45% 45%
35%
511 511
62% 62%
65%
- Selling and Administrative Expenses 234 234
83% 83%
30%
- Research and Development Expense 195 195
51% 51%
25%
82 82
40% 40%
10%
- Depreciation and Amortization 8.02 8.02
16% 16%
1%
EBIT (Operating Income) EBIT 74 74
43% 43%
9%
Net Profit 50 50
858% 858%
6%

In millions AUD.

Don't miss a Thing! We will send you all news about Telix Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Christian Behrenbruch
Founded 2017
Website www.telixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today